107 related articles for article (PubMed ID: 23782099)
21. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
22. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.
Nawrocki ST; Griffin P; Kelly KR; Carew JS
Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561
[TBL] [Abstract][Full Text] [Related]
23. Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus.
Chang PJ; Chen LW; Chen LY; Hung CH; Shih YJ; Wang SS
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701396
[TBL] [Abstract][Full Text] [Related]
24. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
[TBL] [Abstract][Full Text] [Related]
25. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
26. High Efficiency Apoptosis Induction in Breast Cancer Cell Lines by MLN4924/2DG Co-Treatment.
Oladghaffari M; Islamian JP; Baradaran B; Monfared AS; Farajollahi A; Shanehbandi D; Mohammadi M
Asian Pac J Cancer Prev; 2015; 16(13):5471-6. PubMed ID: 26225696
[TBL] [Abstract][Full Text] [Related]
27. The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation.
Andérica-Romero AC; Hernández-Damián J; Vázquez-Cervantes GI; Torres I; González-Herrera IG; Pedraza-Chaverri J
Redox Biol; 2016 Aug; 8():341-7. PubMed ID: 26966893
[TBL] [Abstract][Full Text] [Related]
28. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
29. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.
Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L
Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464
[TBL] [Abstract][Full Text] [Related]
30. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
[TBL] [Abstract][Full Text] [Related]
32. MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death.
Hu L; Bai ZG; Ma XM; Bai N; Zhang ZT
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8273-8280. PubMed ID: 30556867
[TBL] [Abstract][Full Text] [Related]
33. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.
Yang Z; Zhang J; Lin X; Wu D; Li G; Zhong C; Fang L; Jiang P; Yin L; Zhang L; Bie P; Xie CM
Oncol Rep; 2019 Jun; 41(6):3257-3269. PubMed ID: 31002342
[TBL] [Abstract][Full Text] [Related]
35. A metal-based inhibitor of NEDD8-activating enzyme.
Zhong HJ; Yang H; Chan DS; Leung CH; Wang HM; Ma DL
PLoS One; 2012; 7(11):e49574. PubMed ID: 23185368
[TBL] [Abstract][Full Text] [Related]
36. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
[TBL] [Abstract][Full Text] [Related]
37. NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.
Liu X; Jiang Y; Wu J; Zhang W; Liang Y; Jia L; Yu J; Jeong LS; Li L
Biochem Biophys Res Commun; 2017 Jun; 488(1):1-5. PubMed ID: 28450112
[TBL] [Abstract][Full Text] [Related]
38. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.
Li JA; Song C; Rong Y; Kuang T; Wang D; Xu X; Yuan J; Luo K; Qin B; Nowsheen S; Lou Z; Lou W
Cell Cycle; 2018; 17(2):191-199. PubMed ID: 29157102
[TBL] [Abstract][Full Text] [Related]
39. Synaptic structure and function are altered by the neddylation inhibitor MLN4924.
Scudder SL; Patrick GN
Mol Cell Neurosci; 2015 Mar; 65():52-7. PubMed ID: 25701678
[TBL] [Abstract][Full Text] [Related]
40. MLN4924 therapy as a novel approach in cancer treatment modalities.
Oladghaffari M; Islamian JP; Baradaran B; Monfared AS
J Chemother; 2016 Apr; 28(2):74-82. PubMed ID: 26292710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
